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Abstract
The function of pancreatic b-cells is the synthesis and release of insulin, the main hormone involved in blood glucose
homeostasis. Estrogen receptors, ERa and ERb, are important molecules involved in glucose metabolism, yet their role in
pancreatic b-cell physiology is still greatly unknown. In this report we show that both ERa and ERb are present in pancreatic
b-cells. Long term exposure to physiological concentrations of 17b-estradiol (E2) increased b-cell insulin content, insulin
gene expression and insulin release, yet pancreatic b-cell mass was unaltered. The up-regulation of pancreatic b-cell insulin
content was imitated by environmentally relevant doses of the widespread endocrine disruptor Bisphenol-A (BPA). The use
of ERa and ERb agonists as well as ERaKO and ERbKO mice suggests that the estrogen receptor involved is ERa. The up-
regulation of pancreatic insulin content by ERa activation involves ERK1/2. These data may be important to explain the
actions of E2 and environmental estrogens in endocrine pancreatic function and blood glucose homeostasis.
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Introduction
Estrogen receptors are emerging as important molecules for
glucose homeostasis [1]. It is known that ERa knock-out (ERaKO)
mice are obese and insulin resistant [2]. ERa is implicated in b-cell
survival [3]. It has been reported that estrogen function deficiency in
men, due to the absence of ERa or aromatase, results in impaired
glucose metabolism to such an extent that one patient developed
type II diabetes mellitus [4]. Similar abnormalities were found in
aromatase-deficient (ArKO) mice [5]. Recently, it has been
described that both ERa and ERb regulate the glucose transporter
GLUT4 in skeletal muscle [6] and insulin sensitivity in the liver [7].
As described above, the role of estrogen receptors in glucose
metabolism has been mainly studied in tissues other than the
endocrine pancreas. However, the endocrine pancreas is crucial in
the control of blood glucose homeostasis, because b-cells
synthesize and release insulin, the only hormone able to reduce
glycaemia. Therefore, to understand how estrogens affect b-cell
adaptation to physiological situations such as pregnancy, it is
essential to investigate the role of ERa and ERb in this cellular
system.
In addition to the role that estrogen receptors may play in the
physiology of pancreatic b-cells, we should bear in mind that any
disruption of b-cell physiology is associated with the development
of type II diabetes mellitus. Indeed, recent epidemiological reports
link the existence of endocrine disrupting chemicals (EDCs) in
blood, such as persistant organic pollutants (POPs) [8] and
phthalates [9], with type II diabetes and insulin resistance. In
particular, the estrogenic pollutant Bisphenol-A (BPA) was
described as altering pancreatic b-cell function and blood glucose
homeostasis in mice [10].
BPA is the monomer employed to make polycarbonate plastic
and resins used as lining for metal cans and as a plasticizer in other
widely used plastics such as polyvinyl chloride (PVC) and
polyethylene terephthalate (PET). Under normal conditions, this
endocrine disruptor has been shown to leach from food and
beverage containers [11,12] as well as from dental sealants [13].
Widespread human exposure to significant amounts of BPA has
been reported. For example, BPA was found in the urine of 95%
of US citizens [14] and its concentration in human serum ranges
from 0.2–1.6 ng/ml serum (0.88–7.0 nM) [15,16].
The mechanism proposed for BPA actions has been based on its
binding to ERa and ERb, inducing estrogenic signals that modify
gene expression [17]. However, the affinity of BPA for ERs was
reported to be 10,000–100,000-fold lower than that of 17b-
estradiol [18,19] and it was shown to have a lower effect in several
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has been considered to be a weak estrogen.
In this study, we demonstrate that doses of BPA within the
range found in human serum, as well as physiological doses of E2
regulate pancreatic insulin synthesis in intact islets of Langerhans.
This long-term action is mediated by the estrogen receptor ERa.
These results shed light on the role of ERa in the physiology of the
endocrine pancreas and its consequences on blood glucose
homeostasis.
Results
Regulation of insulin content and secretion in intact islets
of Langerhans by 17b-Estradiol
Intact islets of Langerhans from adult male mice were cultured
in the presence of 11mM glucose and increasing concentrations of
E2 for 48 hours. Insulin content increased following an inverted-U
dose-dependent response (Fig. 1A) at doses similar to the
physiological concentrations of E2 observed in the mouse during
pregnancy [21] and in the proestrus stage [22]. Insulin content was
also higher in the majority of single cultured b-cells when
measured with immunocytochemistry (Fig. S1). The islet cell
viability remained high and similar in both E2 and vehicle-treated
islets (Fig. S2). Islet area was unchanged in E2 vs. vehicle-treated
islets (Fig. 1B) and no increase on BrdU incorporation was
observed, indicating no replication of b-cells in response to E2
treatment. Together, these experiments suggest that the increase in
insulin content is not a consequence of an increase in b-cell mass.
We then investigated the possibility that the modulation of
insulin gene expression was responsible for the increase in insulin
content in pancreatic b-cells. A temporal expression profiling of
the insulin mRNA was evaluated by quantitative real time PCR in
cultured islets. As shown in figure 1D, insulin mRNA levels were
induced 1.6 fold 6 hours after islets were exposed to 10nM E2.
Semiquantitative RT-PCR experiments after 48 hours exposure to
E2 gave essentially the same result (Fig. S3).
We next studied whether the aforementioned increase in insulin
content by E2 is accompanied by an alteration in insulin secretion.
The experiment in figure 2A shows that at various stimulatory
glucose concentrations, islets incubated with 1 nM E2 for 48 hours
Figure 1. E2 action on insulin content, b-cell mass and insulin gene expression. (A) Insulin content of islets exposed to increasing doses of
E2 for 48 hours, V means vehicle, (n=8, 8 mice), * p,0.05, ** p,0.01, Mann-Whitney test, compared to vehicle. (B) Average size of islets cultured in
the presence of vehicle (black column) or 1 nM E2 (white column) for 48 hours. Data represent the mean6SEM of at least 60 islets per condition
obtained from 5 different animals. (C) Dispersed islet cells were counted under a fluorescent microscope and results are depicted as a percentage of
BrdU-positive cells, values represent the mean6SEM of 4 independent experiments, each representing 3000 cells per condition. (D) Rat pancreatic
islets were incubated for up to 6 hours in the presence of 10 nM E2. RNA was subsequently isolated and insulin as well as cyclophilin transcript levels
were evaluated by quantitative RT-PCR. Data are presented as fold change of mRNA levels as compared to control untreated islets and normalized to
the cyclophilin transcript. Values represent the mean6SEM of 3 independent experiments performed in duplicates. Statistical significance was tested
by Student’s t test. *, P,0.05; **, P,0.01.
doi:10.1371/journal.pone.0002069.g001
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in insulin release is not the consequence of an alteration in the
stimulus-secretion coupling process, since no change in intracel-
lular calcium concentration dynamics was observed in response to
high glucose (Fig. 2B). None of the parameters analyzed showed
significant differences, basal [Ca
2+]i levels in the absence of stimuli,
increment of [Ca
2+]i in response to glucose (peak size) or the area
under the traces, an indicator of the global Ca
2+ amount entering
into the islet (Fig. 2C–E).
These experiments suggest that physiological concentrations of
E2 produce an increase in insulin gene expression and content
along with an enhanced insulin release in response to stimulatory
glucose concentrations. The results are consistent with the concept
that increased insulin secretion in response to stimulatory glucose
in E2-treated islets may be a consequence of their higher insulin
content. Nonetheless, we cannot rule out the possibility that an
effect of E2 on a-cells may affect insulin release [23–25].
Low doses of BPA increase insulin content in whole islets
of Langerhans
To analyse if environmental estrogens act like the endogenous
hormone we performed similar experiments using BPA instead of
E2. Figure 3A shows a BPA-induced increase of insulin content
following an inverted U-shape dose response curve, with a
significant effect observed at 1 nM and 10 nM BPA when
compared to vehicle exposed islets. Note that 1 nM BPA was
equally effective than E2. Higher concentrations of BPA as 1 mM
produced no increase in insulin content. Therefore BPA, like E2,
increases pancreatic insulin content in a non-monotonic manner.
This non-monotonic behaviour of BPA occurs not only in vitro,
but also in vivo. It was previously described that pancreatic insulin
content increased in response to BPA in vivo [10]. In our study,
mice were exposed daily to 100 mg/kg or 1 mg/kg BPA for 4 days.
We then measured the insulin content of the islets isolated from
BPA or vehicle-treated mice and found that the low dose of BPA
increased insulin content while the high dose had no effect
(Fig. 3B).
Involvement of estrogen receptors in the effect of E2 and
BPA
To determine whether the nuclear estrogen receptors mediate
E2 and BPA effects in islets, we used the pure antiestrogen
ICI182,780, that blocks both ERa and ERb. Figures 4A and B
show that ICI182,780 completely blocks both E2 (Fig 4A) and
BPA (Fig 4B) effects in a dose dependent manner, indicating that
estrogen receptors are involved.
As an initial step towards identifying the ER used by E2 and
BPA to modify insulin content, the expression of ERa and ERb
Figure 2. E2 action on insulin secretion and glucose-induced [Ca
2+]i signals. (A) Glucose-induced insulin secretion from islets exposed to
vehicle (black column) or 1 nM E2 (white column) for 48 hours with 3, 7 and 16mM glucose. (n=3, 5 mice), * p,0.05 Mann-Whitney test compared to
vehicle. (B) Record of fluorescence vs. time from whole islets of Langerhans treated with either vehicle or E2 in the same conditions described for
experiments in figures 1–3. The Ca
2+-dependent fluorescence of Fura-2 is expressed as the ratio F340/F380 (Materials and Methods). Stimuli were
applied when indicated by arrows. (C) Comparison of the fluorescence levels in the absence of stimuli between vehicle and E2-treated islets. (D)
Increment of fluorescence between the fluorescence levels at the peak obtained with high glucose (Rpeak) and the basal fluorescence (Rbasal). (E)
Area under the traces during 10 minutes beginning when R increases in response to glucose. At least 8 islets were used from 3 different mice. Note
that no significant differences were found.
doi:10.1371/journal.pone.0002069.g002
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tochemistry performed on mouse islets of Langerhans confirmed
that b-cells express both ERa and ERb (Fig. 4C–D and Fig. S4).
The location of estrogen receptors in subcellular organelles is
important since they trigger their actions in different cellular
compartments ranging from the plasma membrane to the nucleus
[26]. Both receptors have been reported in the nucleus, cytosol,
mitochondria and associated to the plasma membrane [27–32].
We studied the location of ERa and ERb in whole islets of
Langerhans using immunofluorescence and confocal microscopy.
Both ERa and ERb were present in the cytoplasm and the nucleus
(Fig. 4E, Fig. S5). Overall, our data suggest that both ERa and
ERb are expressed in b-cells and localized inside and outside the
nucleus.
ERa mediates the E2 and BPA-induced increase in insulin
content
In order to evaluate which estrogen receptor is involved in the
effect of 17b-estradiol and BPA, we used the specific agonists for
estrogen receptors, PPT and DPN. The ERa agonist PPT had the
same effect on insulin content as E2 (Fig. 5A). Remarkably, the
increase in insulin content by PPT mimicked the inverted-U dose
response described for E2. However, the ERb agonist DPN
produced no effect at any of the tested concentrations (Fig. 5B),
indicating that the role of ERb in b-cells differs from the one of
ERa. The effect of the ERa agonist PPT was blocked by the
antiestrogen ICI182,780 (Fig. 5C).
To unequivocally demonstrate the extent of ERa activation in
regulating pancreatic insulin content we used islets from ERaKO
and ERbKO mice [33]. The absence of ERa or ERb did not
affect the non-stimulated insulin content of cultured islets when
compared to wild-type mice (Fig. 6A–D). The behavior in terms of
[Ca
2+]i signals induced by glucose was unchanged between wild
type and ERaKO/ERbKO mice (Fig. S6). This result is in
agreement with the normal insulin secretion observed in islets from
ERaKO and ERbKO mice [7]. Islet size was similar between
islets from wild type and KO mice (124266510 mm
2 for ERaWT
and 121236415 mm
2 for ERaKO; 157206612 mm
2 for ERbWT
and 159776764 mm
2 for ERbKO; at least 100 islets from at least
3 different mice).
Exposure to E2 (Fig. 6A, B) or BPA (Fig. 6C, D) strongly
increased insulin content in islets from wild-type mice, yet this
effect was completely abolished in islets from ERaKO mice
(Fig. 6A, C). This effect was observed in vivo, in mice treated with
100 mg/Kg/day for 4 days. No increase in insulin content was
obtained in islets from E2-treated ERaKO mice (Fig. S7). In
contrast, a strong increase in insulin content was observed in E2
and BPA cultured islets from ERbKO mice (Fig. 6B, D). Overall,
these experiments argue strongly that ERa is the main estrogen
receptor involved in the regulation of insulin content by both BPA
and E2.
BPA has been considered a weak estrogen when acting through
ERa and ERE. In our experiments, however, both E2 and BPA
act at equal doses through ERa. It is unlikely that ERa operates
via ERE, because ERE has not been described in the promoters of
mouse insulin genes (types I and II) and the use of the TESS
(Transcription Element Search Software) software [34] did not
reveal any putative ERE. It is known that E2 works as well via
alternative pathways triggered outside the nucleus that involve
either PI3-Kinase or ERKs activation [35,36].
To investigate the involvement of alternative pathways, such as
the MAPK one, we measured the activation of ERK1/2 in
response to PPT. Using antibodies against phosphorylated ERK1/
2, we obtained increased levels of activated ERK1/2 15 minutes
after treatment with the ERa agonist PPT (Fig. 7A and B).
Activation of ERK1/2 occurs in the cytoplasm with no apparent
translocation of activated ERK1/2 to the nucleus (Fig 7A). As
shown in figure 4D, ERa is located in the cytoplasm as well.
Next, we investigated the role that ERKs may have in
regulating pancreatic insulin content following ERa activation.
We exposed cultured islets to either 1 nM of the ERa specific
agonist PPT, BPA or E2, in the presence of specific inhibitors of
ERK1/2, c-Src and PI3K (Fig. 7C). The graph shows that the
increase in insulin content by the three ERa ligands was
completely abolished by the ERK1/2 blocker PD98059. The c-
Src inhibitor PP1 showed a tendency to also inhibit the effect of
the ERa agonists in insulin content, although it is only statistically
significant in the case of BPA. These experiments point to the
possible involvement of ERK1/2 in the ERa regulation of insulin
content.
Discussion
The present work points to a significant role of ERa in the
regulation of insulin synthesis by estrogens. Long-term exposure to
physiological levels of E2 and environmentally relevant doses of
Figure 3. BPA action in vitro and in vivo. (A) Insulin content of islets exposed to increasing doses of BPA for 48 hours, (n=4, 7 mice), * p,0.05. (B)
Insulin content of islets obtained from two sets of experiments. First group: vehicle (black column) and BPA 100 mg/kg/day (white column) treated
mice for four days. Second group: vehicle (black column) and BPA 1 mg/kg/day (white column) treated mice for four days (from at least 3 mice),
*p ,0.05.
doi:10.1371/journal.pone.0002069.g003
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involving activation of ERa.
Results presented here suggest that E2-induced increase of
pancreatic insulin content was a consequence of an up-regulation
of insulin mRNA levels rather than an increase of b-cell viability or
b-cell mass.
Converging evidence from experiments performed with specific
ERs agonists, PPT and DPN, the antiestrogen ICI182,780, as well
as the use of ERaKO and ERbKO mice, have demonstrated that
both E2 and BPA up-regulation of insulin content is mediated by
ERa.
Despite the fact that ERaKO mice are insulin resistant [1], islets
from both ERaKO and ERbKO mice presented normal Ca
2+
signals in response to glucose, indicating that the stimulus secretion
coupling was unaltered. Consequently, insulin secretion in
response to glucose in these islets was unchanged when compared
to WT [7]. Islet area was similar between WT and KO mice
indicating that b-cell mass was unaffected. Furthermore, insulin
Figure 4. Involvement of estrogen receptors in E2 regulation of insulin content. (A) Insulin content obtained in cultured islets exposed to
1 nM E2 in the presence or absence of the antiestrogen ICI 182,780. (n$4, from at least 4 mice), ** p,0.001, compared to vehicle. (B) Insulin content
obtained in cultured islets exposed to 1 nM BPA in the presence or absence of the antiestrogen ICI 182,780. (n=4, 8 mice), ** p,0.01, compared to
vehicle. (C) RT-PCR of mRNA from fresh isolated islets was performed for both ERa and ERb. (D) Confocal images of whole islets stained with anti-
insulin (red) and anti-ERa or anti-ERb (green). (E) ERa and ERb subcellular localization. Single confocal images of whole islets stained with wheat germ
agglutinin (red) as a marker for plasma membrane along with anti-ERa or anti-ERb (green). Calibration bars represent 50 mm.
doi:10.1371/journal.pone.0002069.g004
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for both ERaKO and ERbKO mice. E2 or BPA increase insulin
content in cultured islets from WT and ERbKO mice, while it
remained unchanged in islets from ERaKO mice. The absence of
effect of E2 in increasing insulin content in ERaKO mice was
observed in vivo when mice were treated for 4 days.
The effect of both E2 and BPA occurs following an inverted-U
shape dose-response curve, being significant at doses as low as
Figure 5. Action of ERa and ERb agonists on insulin content. (A) Insulin content of islets cultured for 48 hours in the presence of increasing
doses of the ERa-selective agonist PPT. The bar labeled E2 represents islets cultured with 1 nM E2 for 48 hours. Note that PPT increases insulin
content in an inverted-U dependent manner and its potency is in the same range as E2 (n=5, 7 mice), * p,0.05. (B) The ERb-selective agonist DPN
has no effect at doses from 0.1–100 nM. The bar labeled E2 represents islets cultured with 1 nM E2 for 48 hours (n=4, from at least 5 mice), * p,0.05.
(C) Insulin content regulation by PPT in the presence and absence of ICI182,780 (n=4, from at least 6 mice), * p,0.05.
doi:10.1371/journal.pone.0002069.g005
Figure 6. E2 effect on insulin content in ERaKO and ERbKO mice. (A) Insulin content obtained in cultured islets from wild-type and ERaKO
mice exposed to either vehicle or 1 nM E2. Data obtained from 4 animals for experiments performed with wild-type mice and from 6 animals for
experiments performed with KO mice, *p,0.001 compared to vehicle (B) Insulin content obtained in cultured islets from wild-type and ERbKO mice
exposed to either vehicle or 1 nM E2. Data obtained from 2 animals for experiments performed with wild-type mice and 2 animals for experiments
performed with KO mice, *p,0.05 compared to vehicle (C) Insulin content obtained in cultured islets from wild-type and ERaKO mice exposed to
either vehicle or 1 nM BPA. Data from 4 animals for experiment performed with wild-type mice and 3 animals for experiment performed with KO
mice, *p,0.001 compared to vehicle (D) Insulin content obtained in cultured islets from wild-type and ERbKO mice exposed to either vehicle or 1 nM
BPA. Data from 4 animals for experiment performed with wt mice and 4 animals for experiment performed with KO mice, *p,0.001 compared to
vehicle.
doi:10.1371/journal.pone.0002069.g006
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that the sole activation of ERa is enough to provoke this inverted-
U dose response. The absence of effect of high BPA exposure was
observed in vivo. Although the action of BPA observed in vivo may
reflect the in vitro effect, we must take into account that a regulation
of other parameters by BPA may also contribute, these include
Figure 7. Implication of ERK1/2 in ERa action. A) Levels of ERK1/2 activation. Isolated b-cells were treated with the ERa specific agonist PPT for 0
(Control), 5, 15 and 30 min (PPT). Cells were fixed, permeabilized and incubated with antibodies to phospho-ERK1/2 (in green, p-ERK) and to insulin
(in red, Insulin). Fluorescence images were registered with a confocal laser microscopy system. (B) Fluorescence intensity per cell was quantified as
described in Materials and Methods. The histogram shows the fold increase in fluorescence intensity with respect to control (0 min). Data are pooled
from 4 different experiments. Fluorescence intensity was obtained from at least 200 cells per condition in each experiment. *p=0.01 Student’s t-test
comparing with column at 0 min. (C) Insulin content obtained in cultured islets exposed to either vehicle or 1 nM PPT (black columns), E2 (white
columns) and BPA (grey columns) in the presence of the PI3Kinase inhibitor wortmannin (100 nM), the c-Src inhibitor PP-1 (10 mM) and the ERK1/2
inhibitor PD98059 (10 mM). Data were obtained from at least 4 independent experiments in duplicate using islets from at least 7 different mice. Data
are expressed as fold change as compared to vehicle. *p,0.05, **p,0.01 Student’s t-test comparing pairs marked by lines.
doi:10.1371/journal.pone.0002069.g007
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non-monotonicresponsehasbeen described inother cellular systems
and has important implications for the risk assessment of endocrine
disruptors, since standard testing of xenobiotic estrogenic chemicals
only involves testing a few very high doses [37–39].
In the past, BPA was considered a ‘‘weak’’ estrogen because of its
low binding affinity to both ERa and ERb [18,19], as well as for
having a low transcriptional activity through these ERE binding
receptors [40]. It is rather surprising that the low levels used in our
work have such a large effect, the same as E2, on insulin content up-
regulation. Examples of low dose effects of BPA have been reported
in a wide variety of tissues and cell types [20,37,41], although the
mechanisms of action to explain them are still unclear. One
explanation to be considered is that BPA may act via ERa through
mechanisms other than binding to ERE, through other transcription
factors binding to their respective response elements [42]. Our data
indicate that in b-cells, ERa is located inside and outside the nucleus
anditisknownthatoutsidethenucleusitcanactivateproteinkinases
[43,44]. It is therefore plausible that ERa activation by BPA occurs
at low doses when the response is initiated outside the nucleus
through alternative signalling pathways [26,36,45]. Our results
indicate thatERa activation bythe specificERa agonistPPT rapidly
activates ERK1/2. In addition, increment of pancreatic insulin
content by PPT, E2 and BPA was blocked by the ERK1/2 inhibitor
PD98059.
It is documented that insulin gene transcription is regulated by
ERK1/2 [46,47]. It is also well established that E2 induces rapid
responses through alternative mechanisms that involve ERa and
ERKs [26,35,36,48]. Activation of ERKs by low doses of BPA has
also been reported in rat cerebellar cortex [49].
In addition to the action of BPA described above, the present
report demonstrates that 17b-estradiol increases pancreatic b-cell
insulin mRNA levels, insulin content and insulin secretion at levels
within the range reached during pregnancy and at proestrus stage
[21,22]. During pregnancy, islets adapt to the increased demand
for insulin undergoing major changes in their structure and
function. Among these changes, the increase of insulin synthesis
[50,51] is of great importance. Our results indicate that E2 acting
through ERa may be an important hormone involved in
endocrine pancreas adaptation during pregnancy.
It is important to note that E2-increased insulin content and
secretion will be beneficial when it occurs during an appropriate
period of time and at doses within the physiological range. This may
happen during pregnancy. However, if this estrogenic action occurs
at an inappropriate time, or at doses out of the physiological levels, it
may cause adverse effects such as insulin resistance [10]. This may
happen when there is an exposure to an environmental estrogen,
such as BPA, which causes insulin resistance in healthy male mice
[10]. Therefore the ERa mediated increase of insulin content by
BPA in pancreatic b-cells may contribute to the BPA-provoked
insulin resistance demonstrated in vivo [10].
Materials and Methods
Materials
Fura-2 AM was obtained from Molecular Probes, Inc (Leiden,
The Netherlands), ICI182,780 [52], DPN (Diarylpropionitrile)
[53] and PPT (propylpyrazole triol) [54], PP-1, PD98059 and
Wortmannin from Tocris Cookson Ltd (Avonmouth, UK). Other
substances were obtained from Sigma (Madrid, Spain).
Animals
Swiss albino OF1 male mice (8–10 weeks old) were used. All
animals were kept under standard housing conditions. A
committee on internal animal care and use reviewed and approved
the method used.
ERaKO and ERbKO
Generation and genotyping of both ERbKO and ERaKO mice
are described elsewhere [33]. Adult wild type, ERaKO and
ERbKO animals selected for this study originated from litters of
heterozygous ERa or ERb breeding cages in a pure C57BL/6
genetic background. Institutional guidelines of the Commission
d’Ethique de l’Expe ´rimentation Animale of the University of
Geneva Medical School and the Geneva Veterinarian Office were
followed in the care and use of animals. Islets of Langerhans from
ERaKO and ERbKO animals were treated as described below for
islets from OF-1 mice.
Islet Culture
Pancreatic islets of Langerhans were isolated by collagenase
(Sigma, Madrid, Spain) digestion as previously described [55] and
cultured in groups in RPMI 1640 without phenol-red, containing
11mM glucose (Cambrex,Belgium) at 37uC in a humidified
atmosphere of 95% O2 and 5% CO2 for 48 h. The medium
was supplemented with 10% charcoal dextran treated fetal bovine
serum (Hyclone, USA), 2 mM L-glutamine, 200 U/ml penicillin
and 0.2 mg/ml streptomycin. Stimuli were always present in the
culture media.
Insulin secretion and content measurement
For insulin secretion, the 48 h-cultured islets were washed
during 2 hours with a buffer solution containing (mM) 120 NaCl,
5 KCl, 25 NaHCO3, 1.1 MgCl2 and 2.5 CaCl2, 3 mM D-glucose;
pH 7.35, when gassed with 95% O2 and 5% CO2 . Groups of 5
islets were then incubated in 1 mL of this buffer in the presence of
3, 7, and 16 mM glucose. After 1 hr, the medium was collected,
and insulin was measured in duplicate samples by radioimmuno-
assay using a Coat-a-Count kit (DPC, Los Angeles, CA, USA).
To obtain the insulin content, the islets grouped in batches of 10
were hand picked and incubated overnight in an ethanol/HCl
buffer at 4uC. At the end of the incubation period, the buffer was
removed and studied for insulin content using radioimmunoassay
with a Coat-a-Count kit (DPC). Protein determination was
performed using the Bradford dye method. Insulin and protein
content was determined in each islet sample and the ratio of both
parameters was calculated for each sample. The investigator was
blinded during quantification.
Islet size
Transmission images from isolated whole islets were taken using
a Zeiss axiovert 200 (Zeiss, Madrid, Spain) and a Hamamatsu
Digital Camera C4742-95 (Hamamatsu Photonics, Barcelona,
Spain). Mean islet area was quantified using ORCA image
software from HAMAMATSU (Hamamatsu Photonics, Barce-
lona, Spain).
BrdU incorporation
The islets isolated as described above were dispersed into single
cells with trypsin. Cells were then centrifuged and resuspended in
RPMI 1640 without phenol-red (Cambrex, Belgium) and with
10% charcoal dextran treated serum (Hyclone, USA), 2 mM L-
glutamine, 200 U/ml penicillin and 0.2 mg/ml streptomycin.
They were then plated on glass covers and cultured for 48h in the
presence of 10 mM BrdU (Sigma, Madrid, Spain). After this, the
cells were fixed 2 min with 4% PFA and washed with PBS. The
cells were then treated with 2 N HCl for 20 min at 37uC and three
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achieved with 5 min treatment with 1% Triton X-100. Non-
specific interactions were blocked with PBS+5% normal goat
serum for 1 h. As primary antibody, mouse anti-BrdU (Dako,
M0744) at 1/20 was used overnight at 4uC. As secondary
Antibody, goat anti-mouse Alexa Fluor 488 was used at 1/500 for
1h at room temperature. The nuclei were stainined with 1 mM
Ethidium Homidimer-1 for 15 min at room temperature. BrdU-
positive cells were represented as the percentage of a total number
of 1000 cells per coverslip.
Real Time PCR
Pancreatic islets were isolated from male Wistar rats (Elevage
Janvier, Le Genest-St-Isle, France) by collagenase digestion as
previously described [56]. Islets were cultured for 48 hours in
RPMI1640 supplemented with FBS pre-treated with charcoal.
The latter eliminates endogenous estrogens remaining in FBS.
Subsequently, islets were incubated in the presence of 10 nM 17b-
estradiol for various times (0 to 6 hours). RNA was then extracted
with the RNeasy micro kit (Qiagen,CH) and cDNA generated as
previously described [56]. Primers for cyclophylin and insulin were
designed using the Primer Express Software (Applera Europe,
Rotkreuz, Switzerland) and sequences can be obtained on the
Web page http://phym.unige.ch/groupes/gauthier/index.php.
QT-RT-PCR was performed using an ABI 7500 Sequence
Detection System (Applera Europe) and PCR products were
quantified using the SYBR Green Core Reagent kit. Two distinct
amplifications derived from at least 3 independent experiments
were performed in duplicate for each transcript and mean values
were normalized to the mean value of the reference mRNA
cyclophilin.
Recording [Ca
2+]i
Pancreatic islets of Langerhans were isolated by collagenase
digestion and culturedasdescribed aboveinMaterialsandMethods.
Islets were loaded with 5 mM Fura-2 AM for at least 1 hour at room
temperature. Calcium records in the whole islet of Langerhans were
obtained by imaging intracellular calcium under an inverted
epifluorescence microscope (Zeiss, Axiovert 200). Images were
acquired every ,3s with an extended Hamamatsu Digital Camera
C4742-95 (Hamamatsu Photonics, Barcelona, Spain) using a dual
filter wheel (Sutter Instrument CO, CA, USA) equipped with 340
and 380 nm, 10nm bandpass filters (Omega optics, Madrid, Spain).
Data were acquired using ORCA software from Hamamatsu
(Hamamatsu Photonics, Barcelona, Spain). Fluorescence changes
are expressed as the ratio of fluorescence at 340nm and 380 nm
(F340/F380). Results were plotted and analyzed using commercially
available software (Sigmaplot, Jandel Scientific).
Immunocytochemistry of whole islets
Islets isolated as previously described were fixed with Bouin’s
solution for 5 min and washed with PBS. Then, they were
dehydrated with 30, 50, and 70% ethanol, for 3 min each, and
washed with PBS. After this, islets were treated with 0.5% Triton X-
100 for15 minand thenwashedwithPBS.Thenon-specificstaining
was blocked with PBS supplemented with 0.1% Triton X-100 and
5% serum from the same host as the secondary antibody used. After
the islets had been incubated for 1h at room temperature, primary
antibodies were added to the blocking solution. These were: anti-
insulin (1:200, I2018, Sigma), anti-ERa, G-20 (1:100, sc-544, Santa
Cruz), and anti-ERb, L-20 (1:100, sc-6822, Santa Cruz). The islets
were incubated overnight with the primary antibodiesat 4uC, except
for the anti-ERb, which was kept for 2 days at 4uC. Secondary
antibodies (Alexa FluorH Molecular Probes) were used at 1:1000 in
PBS+0.1% Triton X-100+1% serum from the same host as the
secondary antibody, for 1h at room temperature. To stain
mitochondria, live islets were previously incubated with 500nM
MitotrackerH Red CMXRos (Molecular Probes) for 30 min, then
washed with PBS and fixed as described. To label nuclei, 1 mM
ethidium homodimer-1 (Molecular Probes) was used for 15 min at
room temperature at the end of the protocol. To stain the plasma
membrane, 1 mg/ml wheat germ agglutinin-tetramethylrhodamine
was used (Molecular Probes) and added at the same time as the
primary antibody. A confocal Zeiss Pascal 5 microscope and a Zeiss
10X objective (numerical aperture=0.3) were used too obtain
images for quantification; a Zeiss 40X objective (numerical
aperture=1.3) was used for the rest. The images were analyzed
using LSM Zeiss software (Zeiss, Jena, Germany). Immunofluores-
cence intensity was measured in the plane with maximum
fluorescence. The results were expressed as average pixel intensity
and normalized with respect to the mean value of the pixel intensity
of vehicle-treated islets.
In vivo experiments
BPA was dissolved in tocopherol-stripped corn oil and
administered subcutaneously at the indicated concentration. The
amount of vehicle was kept constant at 100 ml. Swiss albino OF1
male as well as Wild type and ERaKO male mice were injected
twice a day, at 9.00 am and 8.00 pm, with 50 mg/kg or with
500 mg/kg E2 as in the experiment described in figure 3B. Islets
were isolated and insulin content determined as described above.
Viability test
The Live/DeadH Viability/Cytotoxicity kit for mammalian cells
(Molecular Probes) was used to test the viability of the islets of
Langerhans after being cultured for 48h. The manufacturer’s
instructions were followed. After 48h in culture with vehicle or 1
nM E2, islets were incubated with 2 mM calcein and 4 mM
ethidium homodimer-1 for at least 30 min at room temperature,
while gently being shaken. Then the islets were examined using the
previously mentioned confocal microscope and the 40X objective.
Images of 2.5 mm sections of whole islets were taken every 3 mm
and the number of dead cells per islet were counted as nuclei
stained with ethidium homodimer-1.
Immunocytochemistry of isolated cells
Insulin content. The islets isolated as described above were
dispersed into single cells with trypsin. Cells were then centrifuged
and resuspended in RPMI 1640 without phenol-red
(Cambrex,Belgium) and with 10% charcoal dextran treated serum
(Hyclone, USA), 2 mM L-glutamine,200 U/ml penicillin and
0.2 mg/ml streptomycin. They were then plated on 24-well tissue
culture plates and cultured for 48h. After this, the cells were washed
with PBS and fixed as described previously for whole islets. The cells
were first incubated with a monoclonal anti-insulin antibody (1:200
dilution; Sigma, Madrid, Spain) for 2 hr and then for 1 hr with a
secondary antibody, anti-mouse IgG-conjugated fluorescein
isothiocyanate (IgG-FITC; 1:200 dilution; Sigma), both at room
temperature. The cells were washed with PBS overnight. Images
were obtained with a Zeiss Pascal 5 confocal microscope using a
Zeiss 20X objective (numerical aperture=0.5) and analyzed using
LSM Zeiss software (Zeiss, Jena, Germany). We measured
immunofluorescence intensity in random fields. The results were
expressed as average pixel intensity and normalized with respect to
the mean value of the pixel intensity of vehicle-treated cells.
ERK1/2 phosphorylation. The islets isolated as described
above were dispersed into single cells with trypsin. Cells were
plated onto coverslips and incubated for 2 hours in a solution
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NaHCO3 and 2.5 CaCl2, 0.1% BSA; pH 7.35, with 11mM
glucose. After this, the cells were exposed to PPT for 0, 5, 15,
30 minutes, then washed with PBS and fixed as described previously
for whole islets. The cells were then permeabilized with PBS+0.5%
Triton X-100 for 5min and the non-specific binding was blocked
with PBS+5% normal goat serum for 1h at room temperature. The
cells were first incubated with a monoclonal anti-insulin antibody
(1:200 dilution; Sigma, Madrid, Spain) and a rabbit anti-phospho-
p44/42 MAPK (ERK1/2; 1:500; Cell Signaling) for at least 48h at
4uC. Secondary antibodies (Alexa FluorH Molecular Probes) were
used at 1:1000 for 1h at room temperature. Images were obtained
with a Zeiss Pascal 5 confocal microscope using a Zeiss 63X
objective (numerical aperture=1.25) and analyzed using LSM Zeiss
software (Zeiss, Jena, Germany). We measured immunofluorescence
intensity in random fields. The results were expressed as average
pixel intensity and normalized with respect to the mean value of the
pixel intensity of vehicle-treated cells (0 min).
RNA extraction and RT-PCR
RNA was extracted from isolated islets using a commercial kit
(RNeasy, Qiagen) according to the manufacturer’s instructions.
Total RNA was reverse-transcribed by using the First Strand cDNA
Synthesis Kit (AMV, Roche) in a total volume of 20 ml. cDNA was
subjected to PCR amplification by using the Expand High Fidelity
PCR System (Roche Diagnostics). 18S was used as a housekeeping
gene for the semiquantitative RT-PCR. PCR primers were as
follows: Insulin Forward, 59-GAGCCCTAAGTGATCCGCTAC-
39; Insulin Reverse, 59-CAAAGGTTTTATTCATTGCAGAGG-
39; 18S Forward, 59-GGGAGGTAGTGACGAAAAATAAC-39;
18S Reverse, 59-AATCATGGCCTCAGTTCCGAAA-39;E R a
Forward, 59-CATGGAGTCTGCCAAGGAGAC-39;E R a Re-
verse, 59-CAAGAGCAAGTTAGGAGCAAACA-39;E R b For-
ward, 59- AGAACACACCTTGCCTGTAAAC-39;E R b Reverse,
59-CCAGAATCCCTTCCACGCAC-39.5 0ngRN Aa nd3 0cy cl e s
were used for the insulin and 18S PCR and 250 ng and 35 cycles for
the ERa and ERb PCR. The PCR products were separated on 1–
2% agarose gels and visualized by ethidium bromide staining under
UV illumination.
Statistical analysis
Data are expressed as mean6SEM. Pairwise comparisons were
made using Student’s t-test, unless stated otherwise. A probability
level of ,0.05 was considered statistically significant.
Supporting Information
Figure S1 Increase of insulin content in isolated b-cells. Isolated
b-cells were treated with vehicle or E2 for 24–48h, fixed and
stained with anti-insulin antibody. Blue corresponds to low and
red to high fluorescence intensity. The pixel intensity was
measured and normalized. 3 mice were used and at least 150
cells/condition were counted per mouse. * p,0.01, ** p,0.001.
Found at: doi:10.1371/journal.pone.0002069.s001 (8.22 MB TIF)
Figure S2 The increase in insulin content by E2 is not due to an
improvement in cell survival within the islets of Langerhans. Live
cells are stained with calcein (green) and dead cells are stained with
ethidium homodimer-1 (red). (A) Vehicle (Control) and E2-treated
islets. (B) Percentage of dead cells per islet cultured under vehicle
(control) or E2 conditions. A total of 80 cells were counted per
islet, 14 islets were quantified from 3 different animals.
Found at: doi:10.1371/journal.pone.0002069.s002 (7.51 MB TIF)
Figure S3 E2 exposure increases insulin mRNA. (A) Isolated
mouse pancreatic islets were incubated with either vehicle (black
columns) or 1 nM E2 (white column) for 48 hours and then 18S
and insulin mRNA levels were measured by RT-PCR. (B)
Quantification analysis of 4 different experiments (6 mice),
*p ,0.05.
Found at: doi:10.1371/journal.pone.0002069.s003 (3.97 MB TIF)
Figure S4 Presence of ERa and ERb. Immunocytochemistry of
whole islets confirmed the presence of both receptors ERa and
ERb (green). Compare with the experiment performed in the
absence of primary antibodies.
Found at: doi:10.1371/journal.pone.0002069.s004 (5.68 MB TIF)
Figure S5 Location of ERa and ERb. (A) Single confocal images
of whole islets stained with ethidium bromide (red) for the nucleus
and anti-ERa or anti-ERb (green). (B) Single confocal images of
whole islets stained with MitotrackerH (red) for mitochondria and
anti-ERa or anti-ERbantibodies (green). Calibration bars repre-
sent 50 mm
Found at: doi:10.1371/journal.pone.0002069.s005 (9.35 MB TIF)
Figure S6 Glucose-induced Ca
2+ signals in ERaKO and
ERbKO islets. Islets from ERaKO and ERbKO mice show no
difference in the dose-response curve to glucose compared to WT.
Intracellular calcium concentration was measured in isolated islets
from WT and ERaKO and ERbKO mice to different stimulatory
and non-stimulatory glucose concentrations. Representative re-
cords of at least 3 islets per condition.
Found at: doi:10.1371/journal.pone.0002069.s006 (8.49 MB TIF)
Figure S7 E2 treatment in ERaKO mice has no effect. Increase
of insulin content in islets obtained from animals treated with
100 mg/kg/day E2 (white columns) or vehicle (black columns) for
4 days. (A) Data obtained using RIA. Data are expressed as
mean6SEM from 3 independent experiments *p.0.01. (B) Data
obtained using immunocytochemistry. Isolated cells were fixed
and stained with anti-insulin antibody as described in Materials
and Methods. The pixel intensity was measured and normalized.
At least 5000 cells per each condition were counted. * p,0.00001.
Islets were pooled from 3 mice.
Found at: doi:10.1371/journal.pone.0002069.s007 (4.26 MB TIF)
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